John E Levine, MD

John Levine, MD, MS is the Co-Director of the Mount Sinai Acute GVHD International Consortium (MAGIC) and Director of BMT Clinical Research at the Tisch Cancer Institute and a Professor of Internal Medicine and Pediatrics at the Icahn School of Medicine at Mount Sinai. His research program focused on allogeneic hematopoietic cell transplantation with an emphasis on improving outcomes for patients with graft-versus-host disease (GVHD). The centerpiece of Dr. Levine’s research is the MAGIC program, a collaborative effort among over 20 centers in North America, Europe, and Asia, that prospectively studies adult and pediatric recipients of an allogeneic HCT and contains the world’s largest data collection and biorepository dedicated to understanding the biology and clinical course of GVHD. Dr. Levine led the MAGIC effort that created the new international standard for clinical GVHD staging and grading and together with his laboratory collaborator, Dr. James Ferrara, they invented a biomarker blood test that accurately predicts outcomes for patients who require treatment for GVHD. This work has since been translated into clinical trials that test risk-adapted treatments to improve responses and decrease toxicity of GVHD therapy. In addition to his own research program, Dr. Levine has provided leadership to the field as the Chair of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) from 2024-2025 and the Chair of the Cellular Therapy Committee for Children’s Oncology Group (2016-2023).